Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 3, 2013, Pages

  Petta, Salvatore ^a   Rosso, Chiara ^b   Leung, Reynold ^d   Abate, Maria Lorena ^b   Booth, David ^d   Salomone, Federico ^b   Gambino, Roberto ^c   Rizzetto, Mario ^b   Caviglia, Paolo ^b   Smedile, Antonina ^b   Grimaudo, Stefania ^a   Cammà, Calogero ^a   Craxì, Antonio ^a   George, Jacob ^d   Bugianesi, Elisabetta ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cirrhosis; Drug Response; HCV Infection; LDL

Indexed keywords

INTERLEUKIN 28B; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON; RIBAVIRIN; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; FEMALE; GENOTYPE; GENOTYPE 1 CHRONIC HEPATITIS; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; STEATOSIS; TREATMENT RESPONSE;

EID: 84874571977     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.11.022     Document Type: Article

References (40)

1. Bugianesi E., Salamone F., Negro F. The interaction of metabolic factors with HCV infection: does it matter?. J Hepatol 2012, 56(Suppl 1):S56-S65.
2. Lonardo A., Adinolfi L.E., Petta S., et al. Hepatitis C and diabetes: the inevitable coincidence?. Expert Rev Anti Infect Ther 2009, 7:293-308.
3. Vanni E., Abate M.L., Gentilcore E., et al. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 2009, 50:697-706.
4. Bartenschlager R., Penin F., Lohmann V., et al. Assembly of infectious hepatitis C virus particles. Trends Microbiol 2011, 19:95-103.
5. Petta S., Amato M., Cabibi D., et al. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology 2010, 52:1543-1552.
6. Bugianesi E., Marchesini G., Gentilcore E., et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 2006, 44:1648-1655.
7. Adinolfi L.E., Gambardella M., Andreana A., et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001, 33:1358-1364.
8. Castéra L., Hézode C., Roudot-Thoraval F., et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 2004, 53:420-424.
9. Petta S., Cammà C., Di Marco V., et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 2008, 103:1136-1144.
10. Svegliati-Baroni G., Bugianesi E., Bouserhal T., et al. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. Gut 2007, 56:1296-1301.
11. Romero-Gómez M., Del Mar Viloria M., Andrade R.J., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005, 128:636-641.
12. Wang C.S., Wang S.T., Yao W.J., et al. Hepatitis C virus infection and the development of type 2 diabetes in a community based longitudinal study. Am J Epidemiol 2007, 166:136-203.
13. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
14. Thompson A.J., Muir A.J., Sulkowski M.S., et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139:120-129.
15. Tillmann H.L., Patel K., Muir A.J., et al. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol 2011, 55:1195-1200.
16. Rembeck K., Alsiö A., Christensen P.B., et al. Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS One 2012, 7:e29370.
17. Stättermayer A.F., Rutter K., Beinhardt S., et al. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. J Hepatol 2012, 57:492-498.
18. Huang J.F., Yu M.L., Huang C.F., et al. The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy. Liver Int 2012, 32:962-969.
19. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
20. Moucari R., Asselah T., Cazals-Hatem D., et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008, 134:416-423.
21. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994, 20:15-20. The French METAVIR Cooperative Study Group.
22. SAS Technical Report. SAS/STAT software: changes and enhancement, release 6.07 1992, SAS Institute, Inc, Cary, NC.
23. Li J.H., Lao X.Q., Tillmann H.L., et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010, 51:1904-1911.
24. Urban T.J., Thompson A.J., Bradrick S.S., et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010, 52:1888-1896.
25. Wada T., Hoshino M., Kimura Y., et al. Both type I and II IFN induce insulin resistance by inducing different isoforms of SOCS expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2011, 300:E1112-E1123.
26. Schectman G., Kaul S., Mueller R.A., et al. The effect of interferon on the metabolism of LDLs. Arterioscler Thromb 1992, 12:1053-1062.
27. Ehnholm C., Aho K., Huttunen J.K., et al. Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases. Arteriosclerosis 1982, 2:68-73.
28. Shinohara E., Yamashita S., Kihara S., et al. Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Hepatology 1997, 25:1502-1506.
29. Andrade R.J., García-Escaño M.D., Valdivielso P., et al. Effects of interferon-beta on plasma lipid and lipoprotein composition and post-heparin lipase activities in patients with chronic hepatitis C. Aliment Pharmacol Ther 2000, 14:929-935.
30. Abe H., Ochi H., Maekawa T., et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 2010, 53:439-443.
31. Bochud P.Y., Bibert S., Kutalik Z., et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 2012, 55:384-394. Swiss Hepatitis C Cohort Study Group, ANRS HC EP 26 Genoscan Study GroupANRS HC EP 26 Genoscan Study Group.
32. Petta S., Grimaudo S., Cammà C., et al. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. J Hepatol 2012, 56:1356-1362.
33. Falleti E., Bitetto D., Fabris C., et al. Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J Clin Immunol 2011, 31:891-899.
34. Ogawa E., Furusyo N., Murata M., et al. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. J Hepatol 2012, 57:534-540.
35. Petta S., Ferraro D., Cammà C., et al. Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. Antivir Ther 2012, 17:823-831.
36. Bitetto D., Fattovich G., Fabris C., et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011, 53:1118-1126.
37. Moucari R., Forestier N., Larrey D., et al. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut 2010, 59:1694-1698.
38. Serfaty L., Forns X., Goeser T., et al. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut 2012, 61:1473-1480.
39. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206. SPRINT-2 investigators.
40. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416. ADVANCE study team.